All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

potassium phosphate, dibasic 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4206	7758-11-4

Description:

Molecule	Description
Synonyms: potassium phosphate, dibasic dibasic potassium phosphate dipotassium hydrogen orthophosphate dipotassium hydrogen phosphate	Molecular weight: 174.17 Formula: HK2O4P CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 83.42 ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 3, 1975	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sleep disorder	212.26	19.49	101	3654	81465	63403802
Infection	122.58	19.49	104	3651	229069	63256198
Product use issue	107.59	19.49	95	3660	220425	63264842
Treatment failure	85.70	19.49	80	3675	198963	63286304
Rash	68.49	19.49	120	3635	560751	62924516
Myocardial reperfusion injury	41.63	19.49	7	3748	107	63485160
Apallic syndrome	28.76	19.49	7	3748	714	63484553
Malignant neoplasm progression	27.75	19.49	29	3726	82092	63403175
Blood phosphorus decreased	26.64	19.49	10	3745	4443	63480824
Contraindicated product administered	24.33	19.49	45	3710	217603	63267664
Cytokine release syndrome	23.38	19.49	13	3742	14301	63470966
Brain death	21.65	19.49	8	3747	3402	63481865
Disease progression	21.33	19.49	31	3724	122727	63362540
Skin lesion	20.65	19.49	16	3739	30705	63454562
Joint stiffness	20.21	19.49	18	3737	41851	63443416
Mucosal dryness	19.52	19.49	7	3748	2737	63482530

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	65.05	21.02	27	1478	21619	34933807
Drug hypersensitivity	22.23	21.02	22	1483	80507	34874919

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	43.69	17.77	27	3798	44554	79696009
Myocardial reperfusion injury	43.10	17.77	7	3818	107	79740456
Cytokine release syndrome	40.96	17.77	24	3801	35974	79704589
Blood phosphorus decreased	28.25	17.77	11	3814	6657	79733906
Apallic syndrome	28.16	17.77	7	3818	961	79739602
Brain death	19.32	17.77	8	3817	5669	79734894
Mucosal dryness	19.17	17.77	7	3818	3552	79737011

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
CHEBI has role	CHEBI:35225	buffer compounds

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypophosphatemia	off-label use	4996001
Calcium renal calculus	off-label use	427649000
Anuria	contraindication	2472002	DOID:2983
Poisoning by digitalis glycoside	contraindication	12876009
Hyperkalemia	contraindication	14140009
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Sarcoidosis	contraindication	31541009	DOID:11335
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Congenital myotonia, autosomal dominant form	contraindication	57938005
Acute nephropathy	contraindication	58574008
Hypercalcemia	contraindication	66931009	DOID:12678
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Oliguria	contraindication	83128009
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Hyporeninemic hypoaldosteronism	contraindication	236464008
Azotemia	contraindication	445009001
Severe dehydration	contraindication	450316000

🐶 Veterinary Drug Use

Species	Use	Relation
Cattle	Dehydration associated with diarrhea	Indication
Cattle	Early treatment of scouring	Indication
Cattle	Treatment following intravenous fluid therapy	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Re-Sorb, Vytrate	Zoetis Inc.	6

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	POTASSIUM PHOSPHATES	CMP DEV LLC	N212121	Sept. 19, 2019	RX	SOLUTION	INTRAVENOUS	10632150	April 19, 2039	POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018694	VUID
N0000147003	NUI
D02403	KEGG_DRUG
4018694	VANDF
C0138037	UMLSCUI
CHEBI:131527	CHEBI
CHEMBL1200459	ChEMBL_ID
DB09414	DRUGBANK_ID
24450	PUBCHEM_CID
55018	RXNORM
NOCODE	MMSL
007401	NDDF
010466	NDDF
CI71S98N1Z	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	23 sections
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	23 sections
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	23 sections
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	23 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1113	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1113	INJECTION	261 mg	INTRAVENOUS	NDA	20 sections